Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: Do histological assessment and p53 overexpression predict chemo-responsiveness?

Lam, Alfred King‐Yin; Law, Simon; Ma, Lily; Ong, Suyin; Wong, John W.

doi:10.1016/s0959-8049(97)00094-4

Cited by 39 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were a few studies addressed to the role of p53 overexpression in predicting the responsiveness of ESCC to chemoradiation therapy. Although there were some differences between p53 positive and negative tumors in these studies, the difference was not significant [14]. Taken together, p53 mutations appear to play a role in predicting survival of patients though their role in predicting the response to the multi-modality treatment (radiochemotherapy and/or surgery) needs further investigation.…”

Section: P53mentioning

confidence: 64%

Molecular Biology of Esophageal Cancer

et al. 2004

View full text Add to dashboard Cite

Squamous cell carcinoma (ESCC) is the most frequent histological subtype in esophageal cancer, although the incidence of esophageal adenocarcinoma (EAC) is increasing faster than any other malignancy in the western world. New developments in the understanding of molecular mechanisms in esophageal cancer comprise analysis of the genetic tumor profiles by CGH (comparative genomic hybridization), the detection of tumor suppressor gene inactivation, and the analysis of proto-oncogenes. Especially the inactivation of the p53 gene proved to be of particular importance for the development of esophageal cancer. Also p15 and p16 have been identified to be involved in the pathogenesis of esophageal cancer by influencing the cyclin kinase inhibitor cascade and DNA mismatch repair processes. Amplification of cyclin D1 results in growth advantage for tumor cells and enhances tumorigenesis; gene amplification and overexpression of cyclin D1 were frequently demonstrated especially in ESCC. Regarding the dysplasia-metaplasia-carcinoma sequence of Barrett’s esophagus, inhibition of apoptosis by overexpression of bcl-2 proteins occurs as an early event.

show abstract

Section: P53mentioning

confidence: 64%

Molecular Biology of Esophageal Cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Few studies addressed to the role of p53 overexpression in predicting the responsiveness of ESCC to chemoradiation therapy. Although there were some differences between p53 positive and negative tumors in these studies, the difference was not significant [12] .…”

Section: P53mentioning

confidence: 55%

Molecular Biology of Esophageal Cancer

Hao

Brabender

Metzger

et al. 2004

Chinese-German J Clin Oncol

View full text Add to dashboard Cite

There have been many new developments in our understanding of esophageal carcinoma biology over the past several years. Information regarding both of the major forms of this disease, adenocarcinoma and squamous cell carcinoma, has accumulated in conjunction with data on precursor conditions such as Barrett's esophagus. Interesting and promising findings have included overexpression of proto-oncogenes, loss of heterozygosity at multiple chromosomal loci, tumor suppressor gene inactivation, epigenetic silencing by DNA methylation, and mutations and deletions involving the tumor suppressor gene p53. Important cancer pathways, the cyclin kinase inhibitor cascade and the DNA mismatch repair process, implicated in the genesis of multiple tumor types have also been inculpated in esophageal carcinogenesis. Alterations in the p16 and p15 cyclin kinase inhibitors including point mutations and homozygous deletions have been reported in primary esophageal tumors. Further developments in the field of molecular carcinogenesis of esophageal malignancies promise to yield improvements in prevention, early detection, prognostic categorization, and perhaps gene-based therapy of this deadly disease.

show abstract

“…In a meta-analysis examining the correlation between p53 status and response to chemotherapy-based treatment, wild-type p53 gene exhibited an association with pathological complete response in esophageal squamous cell cancer patients who were treated with neoadjuvant chemotherapy (29). However, in the experience of the authors' institution, the correlation between pathological response and p53 expression was not as robust (30).…”

Section: Molecular Predictorsmentioning

confidence: 81%

Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer

Wong

Law

2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Neoadjuvant therapy before esophagectomy is evidence-based, and is a standard-of-care for locally advanced and operable esophageal cancer. However response to such treatment varies in individual patients, from no clinical response to pathological complete response. It has been consistently shown that a good pathological responses is of prognostic value, but perhaps in the expense of those who do not. It is important to identify suitable predictive factors for response, so that patients are not exposed to potentially harmful chemotherapy and/or radiotherapy without benefits. Alternative management strategies can be devised. Various clinical, radiological, serological and potential molecular markers have been studied. None has been shown to be sufficiently reliable to be used in daily practice. Certainly more understanding of the molecular basis for response to chemotherapy/radiotherapy is needed, so that patient treatment can be tailored and individualized.

show abstract

Pre-operative chemotherapy for squamous cell carcinoma of the oesophagus: Do histological assessment and p53 overexpression predict chemo-responsiveness?

Cited by 39 publications

References 16 publications

Molecular Biology of Esophageal Cancer

Molecular Biology of Esophageal Cancer

Molecular Biology of Esophageal Cancer

Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer

Contact Info

Product

Resources

About